Valdecantos et al. employed two NAFLD animal models (MCD diet and HFD mice), which underwent partial hepatectomy after treatment with G49, a dual GLP-1/GCG receptor agonist. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.